Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Lessened by Janus Henderson Group PLC

Janus Henderson Group PLC decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 86.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,473 shares of the biopharmaceutical company's stock after selling 84,661 shares during the quarter. Janus Henderson Group PLC's holdings in Regeneron Pharmaceuticals were worth $9,599,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in the stock. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares during the last quarter. OFI Invest Asset Management bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $28,000. Avalon Trust Co bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $36,000. Crowley Wealth Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $36,000. Finally, Private Wealth Management Group LLC grew its position in Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 39 shares during the period. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 3.1%

Regeneron Pharmaceuticals stock traded up $18.25 during midday trading on Tuesday, hitting $614.79. 1,102,019 shares of the company were exchanged, compared to its average volume of 790,689. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $520.50 and a fifty-two week high of $1,211.20. The company's fifty day moving average price is $598.10 and its 200-day moving average price is $680.17. The company has a market cap of $66.38 billion, a PE ratio of 16.06, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the prior year, the business earned $9.55 earnings per share. The firm's revenue was down 3.7% on a year-over-year basis. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.57%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Wall Street Analyst Weigh In

REGN has been the topic of a number of analyst reports. Cantor Fitzgerald began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 target price on the stock. The Goldman Sachs Group dropped their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Truist Financial reduced their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Citigroup raised shares of Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $600.00 to $700.00 in a research report on Wednesday, May 14th. Finally, Robert W. Baird reduced their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research report on Friday, April 25th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $890.60.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.